PANCREATIC NEUROENDOCRINE TUMOUR

This adverse event was reported 641 times

These drugs are most commonly taken by patients reporting PANCREATIC NEUROENDOCRINE TUMOUR:

# Drug Count
0 OCTREOTIDE ACETATE 178
1 EVEROLIMUS 177
2 SUNITINIB MALATE 79
3 LUTETIUM LU 177 DOTATATE 78
4 METFORMIN 56
5 EVEROLIMUS TABLETS 55
6 METFORMIN ER 500 MG 55
7 METFORMIN ER 750 MG 55
8 CAPECITABINE 52
9 ERGOCALCIFEROL 49
See all common drugs associated with PANCREATIC NEUROENDOCRINE TUMOUR

PANCREATIC NEUROENDOCRINE TUMOUR is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 STREPTOZOCIN 37 0.1609
1 LUTETIUM LU 177 DOTATATE 78 0.0134
2 EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT) 3 0.0062
3 OCTREOTIDE ACETATE 178 0.0058
4 SODIUM CITRATE 5 0.0040
5 EVEROLIMUS 177 0.0036
6 EVEROLIMUS TABLETS 55 0.0032
7 SUNITINIB MALATE 79 0.0020
8 PENICILLIN V POTASSIUM 5 0.0019
9 ERGOCALCIFEROL 49 0.0016
See all drugs enriched for association with PANCREATIC NEUROENDOCRINE TUMOUR

PANCREATIC NEUROENDOCRINE TUMOUR is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Somatostatin Analog [EPC] 45 0.0065
1 Provitamin D2 Compound [EPC] 49 0.0016
2 Endoglycosidase [EPC] 3 0.0016
3 Adrenal Steroid Synthesis Inhibitor [EPC] 1 0.0010
4 Neonatal Fc Receptor Blocker [EPC] 3 0.0007
5 Glinide [EPC] 5 0.0006
6 Nitrogen Binding Agent [EPC] 1 0.0004
7 Kinase Inhibitor [EPC] 181 0.0003
8 Alkylating Drug [EPC] 61 0.0003
9 Topoisomerase Inhibitor [EPC] 19 0.0002
See all drug classes enriched for association with PANCREATIC NEUROENDOCRINE TUMOUR